QuantuMDx completes £11m funding round

 NEWCASTLE UPON TYNE, UK, 24th March 2021. QuantuMDx today announces it has raised £11 million in its latest funding round. Proceeds will be used to complete manufacturing and commercial scale up

Share
Prime Minister, Boris Johnson visits QuantuMDx

NEWCASTLE UPON TYNE, UK, 13 February 2021. QuantuMDx today welcomed the Prime Minister, Rt Hon Boris Johnson MP, for a tour of its purpose-built HQ in Newcastle upon Tyne. QuantuMDx has developed

Share
QuantuMDx response: Government workplace testing announcement

NEWCASTLE UPON TYNE, UK, 7th February 2021. Statement from Jonathan O’Halloran, Chief Executive Officer, QuantuMDx: QuantuMDx welcomes the news from the Government announcing a drive to increase workplace testing in

Share
QuantuMDx’ SARS-CoV-2 test validated for use by NHS Test & Trace

Conclusions verify QuantuMDx’ previous analyses of test performance Results confirm this is one of the most sensitive tests on the market Fulfils the requirements of the MHRA’s Target Product Profile

Share
QuantuMDx SARS-CoV-2 test detects all discovered variants

NEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new variant

Share
QuantuMDx invests £11 million on scale-up to mass manufacture

NEWCASTLE UPON TYNE, UK, 17 December 2020. QuantuMDx today announced it has invested over £11 million to scale up production of its flagship diagnostic device, Q-POC™ and disposable test cassette, to mass

Share
QuantuMDx E-poster presentation: ECCVID 2020

Our Head of Assay Feasibility, Dr John Tyson presented an e-poster at ECCVID last month – the ESCMID Conference on Coronavirus. The e-poster focuses on  the independent, multi centre, clinical performance

Share
White paper: QuantuMDx SARS-CoV-2 RT-PCR Detection Assay – clinical performance evaluation

Title: QuantuMDx SARS-CoV-2 RT-PCR Detection Assay – design, analytical and multi-centre evaluation of clinical performance White paper overview: After completing the development of our SARS-CoV-2 RT-PCR Detection Assay, QuantuMDx undertook

Share
QuantuMDx attains CE-IVD marking for SARS-CoV-2 Test

QuantuMDx Group today announces its SARS-CoV-2 detection assay has been CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within the European Union. QuantuMDx has now registered the

Share
QuantuMDx launches rapid, sensitive SARS-CoV-2 test

QuantuMDx Group today announces the launch of its sensitive SARS-CoV-2 assay for laboratory use, which delivers a result in approximately 70 minutes. Working with British manufacturing partner Biofortuna Limited, QuantuMDx

Share